Similar findings were reported by Burlando et al., who evaluated the effectiveness (namely a reduction in Psoriasis Area Severity Index (PASI) score of 90%) of three different classes of biological agents: TNF-α, IL-17, and IL12/23 inhibitors at weeks 16 and 48 of use. Here, IL17A is linked to psoriasis.